Why is Restasis so expensive?
Restasis (cyclosporine 0.05% ophthalmic emulsion), from Allergan, was formerly only available as a brand name prescription product. Cyclosporine 0.05% ophthalmic emulsion is now available as a more affordable generic option in the U.S.
Like the brand name product Restasis, cyclosporine ophthalmic emulsion has been approved by the FDA to increase tear production in patients with ocular inflammation associated with keratoconjunctivitis sicca, also known as chronic dry eye disease. It is available in single-use vials, but not as a multi-dose bottle.
Learn More: Is there a generic for Restasis eye drops?
Why are brand name drugs so expensive?
Brand name drugs can be expensive because they are the first products on the market and usually do not have a more affordable generic alternative. Manufacturers may price brand name products at high levels to recoup the expenses involved with the original research, drug development and product manufacturing, plus make a profit. There is no competition. This can push up the price greatly.
Original inventors of the drug will have a patent on the product and no other manufacturers can market the generic until the patent expires, which can take 10 years or longer. Drug pricing in the U.S. is complicated and the government does not set drug prices as often happens in other countries.
First-time generics on the market can be expensive too, although not always as expensive as the brand. For example, currently, the only generic manufacturer for cyclosporine 0.05% ophthalmic is Mylan. Because they were the first to market, they do not have generic competition yet. However, as more manufacturers start to make generic cyclosporine, you should see the price go down even further.
Other brands for cyclosporine ophthalmic eye drops for dry eye include Cequa and Verkazia, but there are no generic alternatives for these products yet.
If you are having trouble affording your medication, speak to your healthcare provider, who may have other options. In addition, some manufacturers offer copay savings and other financial assistance for medicines. You can contact them directly.
Related Questions
References
- Ames P, Galor A. Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig (Lond). 2015;5(3):267-285. doi: 10.4155/cli.14.135.
- Viatris is First to Receive FDA Approval of Generic Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease. Press release. Feb 3, 2022. Viatris. Accessed June 3, 2022 at https://newsroom.viatris.com/2022-02-03-Viatris-is-First-to-Receive-FDA-Approval-of-Generic-Restasis-R-Cyclosporine-Ophthalmic-Emulsion-0-05-to-Treat-Dry-Eye-Disease
Read next
Related medical questions
- Can Restasis and Xiidra be used together?
- Does Restasis make your eyelashes fall out?
- Is Restasis a steroid eye drop?
- Is there a Restasis savings or copay card?
- How does Xiidra differ from OTC dry eye treatments?
- How many times can you use a vial of Restasis?
- Is Restasis safe for long-term use?
- How long does it take for Restasis to work?
- Can you use other eye drops with Restasis?
- Does Restasis need to be refrigerated?
- How effective is Restasis for dry eyes?
Drug information
- Restasis Information for Consumers
- Restasis prescribing info & package insert (for Health Professionals)
- Side Effects of Restasis (detailed)
Related support groups
- Restasis (32 questions, 44 members)